Arbutus appoints lisa m. caperelli as vice president, investor relations

Warminster, pa., sept. 21, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis b virus (hbv) infection, as well as therapies to treat coronaviruses (including covid-19), today announced the company has appointed lisa m. caperelli to the newly created position of vice president of investor relations, leading investor relations strategy and communications activities, reporting to david hastings, arbutus' chief financial officer.
ABUS Ratings Summary
ABUS Quant Ranking